Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.
NPJ Vaccines
; 9(1): 17, 2024 Jan 20.
Article
en En
| MEDLINE
| ID: mdl-38245545
ABSTRACT
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-MTM adjuvanted vaccines predominantly elicits immune events in local tissues with little spillover to the periphery. A third dose of an updated vaccine based on the Gamma (P.1) variant 7 months after two immunizations with licensed NVX-CoV2373 resulted in significant enhancement of anti-spike antibody titers and antibody breadth including neutralization of forward drift Omicron variants. The third immunization expanded the Spike-specific memory B cell pool, induced significant somatic hypermutation, and increased serum antibody avidity, indicating considerable affinity maturation. Seven months after immunization, vaccinated animals controlled infection by either WA-1 or P.1 strain, mediated by rapid anamnestic antibody and T cell responses in the lungs. In conclusion, a third immunization with an adjuvanted, low-dose recombinant protein vaccine significantly improved the quality of B cell responses, enhanced antibody breadth, and provided durable protection against SARS-CoV-2 challenge.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
NPJ Vaccines
Año:
2024
Tipo del documento:
Article
País de afiliación:
Suecia